Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Operations (2016 - 2025)

Catalyst Pharmaceuticals' Cash from Operations history spans 16 years, with the latest figure at 44891000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 36.66% year-over-year to 44891000.0; the TTM value through Dec 2025 reached 208670000.0, down 12.98%, while the annual FY2025 figure was 208670000.0, 12.98% down from the prior year.
  • Cash from Operations reached 44891000.0 in Q4 2025 per CPRX's latest filing, up from 32438000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 72871000.0 in Q3 2024 to a low of 3814000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 38424850.0, with a median of 36257500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: skyrocketed 164.5% in 2024, then plummeted 55.49% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 19176000.0 in 2021, then soared by 109.0% to 40077000.0 in 2022, then skyrocketed by 38.85% to 55648000.0 in 2023, then increased by 27.37% to 70877000.0 in 2024, then plummeted by 36.66% to 44891000.0 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Cash from Operations are 44891000.0 (Q4 2025), 32438000.0 (Q3 2025), and 71298000.0 (Q2 2025).